Euphorbiasteroid Abrogates EGFR and Wnt/β-Catenin Signaling in Non-Small-Cell Lung Cancer Cells to Impart Anticancer Activity

EGFR and Wnt/beta-catenin signaling pathways play a prominent role in tumor progression in various human cancers including non-small-cell lung carcinoma (NSCLC). Transactivation and crosstalk between the EGFR and Wnt/beta-catenin pathways may contribute to the aggressiveness of cancers. Targeting these oncogenic pathways with small molecules is an attractive approach to counteract various types of cancers. In this study, we demonstrate the effect of euphorbiasteroid (EPBS) on the EGFR and Wnt/beta-catenin pathways in NSCLC cells. EPBS induced preferential cytotoxicity toward A549 (wildtype EGFR-expressing) cells over PC-9 (mutant EGFR-expressing) cells. EPBS suppressed the expression of EGFR, Wnt3a, beta-catenin, and FZD-1, and the reduction in beta-catenin levels was found to be mediated through the activation of GSK-3 beta. EPBS reduced the phosphorylation of GSK-3 beta(S9) with a parallel increase in beta-TrCP and phosphorylation of GSK-3 beta(Y216). Lithium chloride treatment increased the phosphorylation of GSK-3 beta(S9) and nuclear localization of beta-catenin, whereas EPBS reverted these effects. Forced expression or depletion of EGFR in NSCLC cells increased or decreased the levels of Wnt3a, beta-catenin, and FZD-1, respectively. Overall, EPBS abrogates EGFR and Wnt/beta-catenin pathways to impart its anticancer activity in NSCLC cells.